Roche Believes Biomarker Could Position Antibody For Severe Asthma For Success
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
During an investor presentation Nov. 7, the Swiss pharma outlined its plans to move lebrikizumab into Phase III next year.
You may also be interested in...
Roche's Lebrikizumab Shows Potential For Biomarker Targeting In Asthma
Phase II data published in NEJM show that biomarker-assisted therapies could be valuable in targeting the variabilities of the disease.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.